期刊
CIRCULATION
卷 129, 期 25, 页码 S1-S45出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/01.cir.0000437738.63853.7a
关键词
AHA Scientific Statements; cardiovascular disease; cholesterol; hydroxymethylglutaryl-CoA reductase inhibitors/statins; primary prevention; secondary prevention; diabetes mellitus; drug therapy; risk assessment; risk reduction behavior; patient compliance; hypercholesterolemia; lipids; biomarkers, pharmacological